WMJ-J-09 是一种 HDAC 抑制剂,对 HDAC1、HDAC2、HDAC3、HDAC8、HDAC6 和 HDAC4 的 IC50 分别为 7.5 nM、21.3 nM、18.4 nM、90.9 nM、3.9 nM 和 8715.7 nM,可通过抑制 HDAC 酶活性导致关键蛋白乙酰化,并经 LKB1-AMPK-p38MAPK-p63-存活素信号级联反应在癌细胞中阻滞细胞周期、诱导细胞凋亡(Apoptosis),从而调控癌细胞死亡,可用于结直肠癌和头颈部鳞状细胞癌的研究。
产品编号: MS-L40048 纯度: 98.44% CAS No.: 2416914-29-7 分子式: C22H27N3O5S 分子量: 445.53
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

WMJ-J-09 是一种 HDAC 抑制剂,对 HDAC1、HDAC2、HDAC3、HDAC8、HDAC6 和 HDAC4 的 IC50 分别为 7.5 nM、21.3 nM、18.4 nM、90.9 nM、3.9 nM 和 8715.7 nM,可通过抑制 HDAC 酶活性导致关键蛋白乙酰化,并经 LKB1-AMPK-p38MAPK-p63-存活素信号级联反应在癌细胞中阻滞细胞周期、诱导细胞凋亡(Apoptosis),从而调控癌细胞死亡,可用于结直肠癌和头颈部鳞状细胞癌的研究。

生物实验数据

生物活性 WMJ-J-09 is an HDAC inhibitor with IC50 values of 7.5 nM (HDAC1), 21.3 nM (HDAC2), 18.4 nM (HDAC3), 90.9 nM (HDAC8), 3.9 nM (HDAC6), and 8715.7 nM (HDAC4), which inhibits HDAC enzyme activity to induce acetylation of key proteins and regulates cancer cell death by arresting the cell cycle and inducing apoptosis in cancer cells through the LKB1-AMPK-p38MAPK-p63-survivin signaling cascade, and can be used for research on colorectal cancer and head and neck squamous cell carcinoma.
IC50 & Target HCT116 Cells:~ 5 uM
体外研究
(In Vitro)

WMJ-J-09 (compound WMJ-J-09) (0-10 μM, 48 h, CRC cells) (0-20 μM, 72 h, HNSCC cells) 具有浓度和时间依赖性,选择性杀伤癌细胞,对非肿瘤 FHC 细胞无显著毒性。
WMJ-J-09 (5 μM, 24 h, HCT116 cells) (10 μM, 48 h, FaDu cells) 在G2/M期阻滞癌细胞的细胞周期,诱导细胞凋亡。
WMJ-J-09 (5 μM, 24 h, HCT116 cells) (10 μM, 24 h, FaDu cells) 破坏微管组装。
WMJ-J-09 (5 μM, 6-24 h, HCT116 cells) (10 μM, 24 h, FaDu cells) 在转录水平抑制Survivin。
WMJ-J-09 (0-10 μM, 24 h, HCT116 cells) (0-20 μM, 48 h, FaDu cells) 在癌细胞中可以控制信号通路,并抑制 HDAC 来调控关键蛋白,促进癌凋亡。

Cell Viability Assay

Cell Line: HCT116 cells, FHC cells; FaDu cells, SCC9 cells, SCC25 cells
Concentration: 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM (HCT116 cells, FHC cells); 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells, SCC9 cells, SCC25 cells)
Incubation Time: 48 h (HCT116 cells, FHC cells); 72 h (FaDu cells, SCC9 cells, SCC25 cells)
Result: Reduced the viability of CRC cells (with significant inhibition at 10 μM and an IC50 of approximately 5 μM).
Had the strongest inhibitory effect on cell viability at 10 μM, and the survival rate of FaDu cells dropped to about 30 % after treatment with 20 μM for 72 h.

Apoptosis Analysis

Cell Line: HCT116 cells; FaDu cells
Concentration: 5 μM (HCT116 cells); 10 μM (FaDu cells)
Incubation Time: 24 h (HCT116 cells); 48 h (FaDu cells)
Result: Increased the proportion of early apoptotic (LR quadrant) and late apoptotic (UR quadrant) cells.
Increased cleaved caspase-3 and PARP cleavage fragments.
Significantly increased the proportion of sub-G1 phase (apoptotic cells), with approximately 40 % at 20 μM.

Cell Cycle Analysis

Cell Line: HCT116 cells; FaDu cells
Concentration: 5 μM (HCT116 cells); 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells)
Incubation Time: 24 h
Result: Reduced the proportion of cells in the S phase and increased the proportion of cells in the G2/M phase and sub-G1 phase (apoptosis peak).
Increased the proportion of cells in the G2/M phase (from 12 % to 28 % at 10 μM) and decreased the number of cells in the S phase.

Immunofluorescence

Cell Line: HCT116 cells; FaDu cells
Concentration: 5 μM (HCT116 cells); 10 μM (FaDu cells)
Incubation Time: 24 h
Result: Disrupted the cytoskeleton through α-tubulin acetylation.

RT-PCR

Cell Line: HCT116 cells; FaDu cells
Concentration: 5 μM (HCT116 cells); 10 μM (FaDu cells)
Incubation Time: 6-24 h (HCT116 cells); 6 h (FaDu cells)
Result: Inhibited survivin expression at the transcriptional level.

Western Blot Analysis

Cell Line: HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells; FaDu cells
Concentration: 0.1 μM, 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM (HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells); 2.5 μM, 5 μM, 10 μM, 20 μM (FaDu cells)
Incubation Time: 24 h (HCT116 cells, HCT116 p53-/- cells, HCT116-p53 wildtype cells); 48 h (FaDu cells)
Result: Increased p21 protein, acetylated and phosphorylated p53, decreased survivin protein, and increased α-tubulin acetylation.
Activated phosphorylation of the LKB1/p38MAPK pathway.
Acetylated survivin and degraded it in the proteasome.
Increased p21 protein significantly, while cyclin D1 and survivin proteins decreased.
Increased the phosphorylation levels of LKB1 (Ser 428), AMPK (Thr 172), p38MAPK (Thr 180/Tyr 182), and p63 (Ser 160/162) over time, and increased cleaved caspase-3 and PARP (apoptosis markers).
体内研究
(In Vivo)

WMJ-J-09 (化合物WMJ-J-09) (20 mg/kg, i.p, 每日一次,持续19天) 通过抑制癌细胞增殖来抑制 CRC 肿瘤生长,并且在 HCT116 异种移植小鼠模型中耐受性良好。

WMJ-J-09 (20 mg/kg, i.p, 每日一次,持续23天) 可抑制头颈部鳞状细胞癌移植瘤的生长,且安全性良好。

Animal Model: HCT116 xenograft model established in nude male mice(4 weeks)
Dosage: 20 mg/kg
Administration: Daily intraperitoneal injection (i.p.), at the corresponding doses for 19 days
Result: Inhibited tumor growth, with tumor volume and weight significantly lower than those in the control group.
Inhibited tumor proliferation, as indicated by reduced Ki67 immunohistochemical staining within the tumor.
Exhibited low toxicity, with no significant change in mouse body weight.
Animal Model: DaFu xenograft model established in nude male mice(4 weeks, 25g)
Dosage: 20 mg/kg
Administration: Daily intraperitoneal injection (i.p.), at the corresponding doses for 23 days.
Result: Significantly inhibited tumor growth, with the average tumor weight in the treatment group lower than that in the control group.
Exhibited low toxicity, with no significant change in mouse body weight.
性状 固体
颜色 White to off-white

化学信息

分子量 445.53
分子式 C22H27N3O5S
CAS No. 2416914-29-7

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 250 mg/mL (561.13 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.2445 mL11.2226 mL22.4452 mL56.1129 mL
5 mM0.4489 mL2.2445 mL4.4890 mL11.2226 mL
10 mM0.2245 mL1.1223 mL2.2445 mL5.6113 mL
15 mM0.1496 mL0.7482 mL1.4963 mL3.7409 mL
20 mM0.1122 mL0.5611 mL1.1223 mL2.8056 mL
25 mM0.0898 mL0.4489 mL0.8978 mL2.2445 mL
30 mM0.0748 mL0.3741 mL0.7482 mL1.8704 mL
40 mM0.0561 mL0.2806 mL0.5611 mL1.4028 mL
50 mM0.0449 mL0.2245 mL0.4489 mL1.1223 mL
60 mM0.0374 mL0.1870 mL0.3741 mL0.9352 mL
80 mM0.0281 mL0.1403 mL0.2806 mL0.7014 mL
100 mM0.0224 mL0.1122 mL0.2245 mL0.5611 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础